

23 April 2019





## ASX ANNOUNCEMENT

### Amended Appendix 3B

engage:BDR Limited (ASX: EN1) (“engage:BDR” or “the Company”) provides the attached amended Appendix 3B following the Company’s announcement dated 18 April 2019.

It is noted that the total number of Series 2 convertible notes which were converted should have been noted at section 6 of the Appendix 3B as 140,000 unlisted Series 2 convertible notes with 100,000 Series 2 Convertible Notes remaining on issue following the conversion.

The attached amended Appendix 3B reflects the issued capital following the conversion.

On behalf of the Board  
Ted Dhanik  
Co-Founder and Executive Chairman  
engage:BDR Limited  
+1(310)954-0751  
[info@EN1.com](mailto:info@EN1.com)  
[twitter.com/TedDhanik](https://twitter.com/TedDhanik)  
[linkedin.com/in/TedDhanik](https://www.linkedin.com/in/TedDhanik)  
Follow us on social media:  
     
[facebook.com/engageBDR](https://www.facebook.com/engageBDR)  
[linkedin.com/company/engage-BDR](https://www.linkedin.com/company/engage-BDR)  
[twitter.com/engageBDR](https://twitter.com/engageBDR)  
[instagram.com/engageBDR](https://www.instagram.com/engageBDR)

**USA**  
engage:BDR  
9220 Sunset Blvd, Suite 100  
West Hollywood, CA 90069  
USA  
+1 310 954 0751  
[info@engagebdr.com](mailto:info@engagebdr.com)

**Australia**  
Scottish House Level 4 90 William  
Street  
Melbourne Victoria 3000  
AUSTRALIA  
+61 412 111 821  
[info@engagebdr.com.au](mailto:info@engagebdr.com.au)

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

engage:BDR Limited

ACN

621 160 585

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |  |   |
|---|--|---|
| 1 | +Class of +securities issued or to be issued   | 1. Fully paid ordinary shares<br>2. Fully paid ordinary shares<br>3. Fully paid ordinary shares |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | 1. 7,504,000<br>2. 1,136,945<br>3. 15,602,041   |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | 1. Fully paid ordinary shares<br>2. Fully paid ordinary shares<br>3. Fully paid ordinary shares |

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

4	<p>Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	Yes
5	Issue price or consideration	<ol style="list-style-type: none"> <li>1. Deemed issue price of \$0.039 (3.9 cents) per share.</li> <li>2. \$0.049 (4.9 cents)</li> <li>3. \$0.049 (4.9 cents)</li> </ol>
6	<p>Purpose of the issue          (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<ol style="list-style-type: none"> <li>1. Issue of fully paid ordinary shares upon conversion 140,000 unlisted Series 2 convertible notes and 70,000 unlisted Series 3 convertible notes.</li> <li>2. Shares issued in relation to settlement of outstanding liabilities.</li> <li>3. Shares issued in relation to settlement of outstanding creditor balances.</li> </ol>
6a	<p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the +securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	Yes
6b	The date the security holder resolution under rule 7.1A was passed	31 May 2018
6c	Number of +securities issued without security holder approval under rule 7.1	Nil
6d	Number of +securities issued with security holder approval under rule 7.1A	Nil
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<ol style="list-style-type: none"> <li>1. 7,504,000 fully paid ordinary shares – 1 April 2019</li> <li>2. 1,136,945 fully paid ordinary shares – 1 April 2019</li> <li>3. 15,602,041 fully paid ordinary shares – 1 April 2019</li> </ol>

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

6f	Number of securities issued under an exception in rule 7.2	Nil	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1	
7	Dates of entering +securities into uncertificated holdings or despatch of certificate	18 April 2019	
8	Number and +class of all +securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	Number	+Class
		486,354,115	Ordinary fully paid shares
		33,999,993	Listed Options exercisable at \$0.25 (25 cents) per option by 14 December 2020 (ENiO).
9	Number and +class of all +securities not quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	100,000	Unlisted convertible notes issued at USD\$0.90 per Note with a face value of USD\$1.00 per Note. Notes are secured with a Maturity date of 30 January 2020 ( <b>Series 2 Notes</b> ).
		730,000	Unlisted convertible notes issued at USD\$0.90 per Note with a face value of USD\$1.00 per Note. Notes are secured with a Maturity date of 8 April 2020. ( <b>Series 3 Notes</b> )
		8,676,093	Unlisted options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

**Part 2 - Bonus issue or pro rata issue**

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	+Class of +securities to which the offer relates	N/A
15	+Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has +security holders who will not be sent new issue documents  <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of <sup>+</sup> security holders	N/A
25	If the issue is contingent on <sup>+</sup> security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do <sup>+</sup> security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Despatch date	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

**Part 3 - Quotation of securities**

*You need only complete this section if you are applying for quotation of securities*

34 Type of securities  
(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

**Entities that have ticked box 34(a)**

**Additional securities forming a new class of securities**

*Tick to indicate you are providing the information or documents*

35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities

**Entities that have ticked box 34(b)**

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

---

+ See chapter 19 for defined terms.

<p>40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ol style="list-style-type: none"> <li>1. the date from which they do</li> <li>2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ol>	<p>N/A</p>
--	------------

<p>41 Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another security, clearly identify that other security)</p>	<p>N/A</p>
---	------------

<p>42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%; padding: 5px;">Number</th> <th style="width: 50%; padding: 5px;">+Class</th> </tr> </thead> <tbody> <tr> <td style="height: 80px;"></td> <td></td> </tr> </tbody> </table>	Number	+Class		
Number	+Class				

+ See chapter 19 for defined terms.



**Appendix 3B**  
**New issue announcement**


---

**Quotation agreement**

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
  
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  
  - There is no reason why those +securities should not be granted +quotation.
  
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
  
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
  
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here  .....  
(Director)

Date: 18 April 2019

Print name: Ted Dhanik

== == == == ==

---

+ See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

### Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>																																									
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>																																									
<b>Insert</b> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	252,445,579																																								
<p><b>Add</b> the following:</p> <ul style="list-style-type: none"> <li>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	<table style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%;"></td><td style="width: 50%; text-align: right;">12,500,000 – 10 May 2018</td></tr> <tr><td></td><td style="text-align: right;">2,250,000 – 10 May 2018</td></tr> <tr><td></td><td style="text-align: right;">1,290,625 - 15 June 2018</td></tr> <tr><td></td><td style="text-align: right;">3,750 - 31 August 2018</td></tr> <tr><td></td><td style="text-align: right;">4,548,498 – 31 August 2018</td></tr> <tr><td></td><td style="text-align: right;">6,523,453 – 31 August 2018</td></tr> <tr><td></td><td style="text-align: right;">5,458,200 – 12 September 2018</td></tr> <tr><td></td><td style="text-align: right;">3,100,000 – 30 November 2018</td></tr> <tr><td></td><td style="text-align: right;">25,099,423 – 25 January 2019</td></tr> <tr><td></td><td style="text-align: right;">1,900,000 – 30 January 2019</td></tr> <tr><td></td><td style="text-align: right;">13,471,396 – 30 January 2019</td></tr> <tr><td></td><td style="text-align: right;">9,028,597 – 5 February 2019</td></tr> <tr><td></td><td style="text-align: right;">7,498,236 – 18 February 2019</td></tr> <tr><td></td><td style="text-align: right;">10,519,735 - 8 March 2019</td></tr> <tr><td></td><td style="text-align: right;">11,347,597 – 18 March 2019</td></tr> <tr><td></td><td style="text-align: right;">17,719,531 – 20 March 2019</td></tr> <tr><td></td><td style="text-align: right;">25,848,790 – 2 April 2019</td></tr> <tr><td></td><td style="text-align: right;">13,220,706 – 5 April 2019</td></tr> <tr><td></td><td style="text-align: right;">749,810 – 8 April 2019</td></tr> <tr><td></td><td style="text-align: right;">24,242,986 – 18 April 2019</td></tr> </table>		12,500,000 – 10 May 2018		2,250,000 – 10 May 2018		1,290,625 - 15 June 2018		3,750 - 31 August 2018		4,548,498 – 31 August 2018		6,523,453 – 31 August 2018		5,458,200 – 12 September 2018		3,100,000 – 30 November 2018		25,099,423 – 25 January 2019		1,900,000 – 30 January 2019		13,471,396 – 30 January 2019		9,028,597 – 5 February 2019		7,498,236 – 18 February 2019		10,519,735 - 8 March 2019		11,347,597 – 18 March 2019		17,719,531 – 20 March 2019		25,848,790 – 2 April 2019		13,220,706 – 5 April 2019		749,810 – 8 April 2019		24,242,986 – 18 April 2019
	12,500,000 – 10 May 2018																																								
	2,250,000 – 10 May 2018																																								
	1,290,625 - 15 June 2018																																								
	3,750 - 31 August 2018																																								
	4,548,498 – 31 August 2018																																								
	6,523,453 – 31 August 2018																																								
	5,458,200 – 12 September 2018																																								
	3,100,000 – 30 November 2018																																								
	25,099,423 – 25 January 2019																																								
	1,900,000 – 30 January 2019																																								
	13,471,396 – 30 January 2019																																								
	9,028,597 – 5 February 2019																																								
	7,498,236 – 18 February 2019																																								
	10,519,735 - 8 March 2019																																								
	11,347,597 – 18 March 2019																																								
	17,719,531 – 20 March 2019																																								
	25,848,790 – 2 April 2019																																								
	13,220,706 – 5 April 2019																																								
	749,810 – 8 April 2019																																								
	24,242,986 – 18 April 2019																																								
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	-																																								
<b>“A”</b>	452,066,946																																								

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

<b>Step 2: Calculate 15% of “A”</b>	
<b>“B”</b>	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A” by 0.15</b>	67,810,041
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	<p>484,539 – 15 June 2018</p> <p>589,300 – 28 February 2019</p> <p>909,091 – 28 February 2019</p> <p>1,090,909 – 28 February 2019</p> <p>18,607,945 – 28 February 2019</p> <p>137,405 - 8 March 2019</p> <p>4,000,000 - 8 March 2019</p> <p>12,467,980 – 18 March 2019</p>
<b>“C”</b>	38,287,169
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	67,810,041
<p><b>Subtract “C”</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	38,287,169
<b>Total [“A” x 0.15] – “C”</b>	<b>29,522,872</b> <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b> <i>Note: number must be same as shown in Step 1 of Part 1</i>	452,066,946
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10 <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	45,206,695
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <b>Notes:</b> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	-
<b>“E”</b>	-

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

**Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A**

“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	45,206,695
<b>Subtract “E”</b> <i>Note: number must be same as shown in Step 3</i>	-
<b>Total</b> [“A” x 0.10] – “E”	<b>45,206,695</b>

---

+ See chapter 19 for defined terms.